Neurotrophic Keratitis Epidemiology

• In 2023, the prevalence of Neurotrophic keratitis was highest in the US among the 7MM, accounting for nearly 66.6 thousand cases which is further expected to increase by 2034.
• In the United States, in 2023, ~13 thousand males and ~19 thousand females were affected with Neurotrophic Keratopathy.
• The severity-specific diagnosed prevalent cases of Neurotrophic Keratitis are divided into the following groups: Stage 1 (epithelial alterations), Stage 2 (persistent epithelial defects), and Stage 3 (corneal ulcers). In the United States, a higher number of cases were observed in the Stage 3 (corneal ulcers) compared to others, comprising around 14,868 thousand cases in 2023.
• Among EU4 and the UK, the UK had the highest diagnosed prevalent population of Neurotrophic Keratitis, with 18,547 cases, followed by Germany and France in 2023.
• As per DelveInsight’s estimates, Japan accounted for nearly 9% of the Total Diagnosed Prevalent Cases of Neurotrophic Keratitis in the 7MM in 2023.

DelveInsight’s “Neurotrophic Keratitis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Neurotrophic Keratitis, historical and forecasted epidemiology of Neurotrophic Keratitis in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan 

Study Period: 2021-2034

Neurotrophic Keratitis Disease Understanding  

Neurotrophic Keratitis Overview

Neurotrophic keratitis, which is also known as Neurotrophic Keratopathy or trigeminal neuropathic keratopathy, is a rare degenerative corneal disease characterized by symptoms like lack of or decreased corneal sensation, corneal epithelial breakdown and impaired healing that results in increased susceptibility of the corneal surface to injury and compromised healing. In severe cases, this can also lead to stromal melting, corneal ulceration, and even perforation.

Neurotrophic Keratitis Diagnosis

Neurotrophic Keratitis is diagnosed by careful investigation of any of the ocular and systemic conditions associated with the disease, along with quantitatively measuring the cornea’s sensitivity. Neurotrophic Keratitis has three different stages/severity levels: Stage I, II, and III. Timely diagnosis is very important for early-stage detection.

Further details related to diagnosis are provided in the report…

Neurotrophic Keratitis Epidemiology

For the purpose of designing the patient-based model for the Neurotrophic Keratitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Prevalent Cases of Neurotrophic Keratitis, Total Diagnosed Prevalent Cases of Neurotrophic Keratitis, Gender-specific Diagnosed Prevalent Cases of Neurotrophic Keratitis, and Severity-specific Diagnosed Prevalent cases of Neurotrophic Keratitis in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2021 to 2034. 

• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Neurotrophic keratitis in the 7MM were nearly 65 thousand in 2023.
• The highest total diagnosed prevalent cases of Neurotrophic keratitis were accounted by the US in 2023 (33 thousand), which are expected to show a rise in the future.
• Among the European countries, the United Kingdom had the highest diagnosed prevalent cases of neurotrophic keratitis with ~8 thousand cases, followed by Germany, which had diagnosed prevalent population of ~6 thousand in 2023. On the other hand, Spain had the lowest prevalent population (3 thousand cases).
• Japan had nearly 5 thousand total diagnosed prevalent cases of Neurotrophic keratitis in 2023, accounting for approximately 8% in 7MM.
• Based on stage-specific segmentation, the people in Stage 3 were affected the most by Neurotrophic Keratitis in the US, accounting for approximately 14 thousand cases in 2023.
• The DelveInsight analysis indicates that among the EU4 and the UK, females were more affected than males, with approximately 16 thousand female cases and 11 thousand male cases in 2023.

Diagnosed Prevalent Cases of Neurotrophic Keratitis Cases in the 7MM

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence. 

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, US; Ospedale San Raffaele di Milano-IRCCS, Milan, Italy; Heinrich-Heine University Duesseldorf, Germany; Hôpital Bichat–Claude-Bernard, Paris, France; Department of Radiation Oncology, IRCCS San Matteo Polyclinic Foundation, Pavia, Italy; Nottingham University Hospitals, NHS Trust, Nottingham, England, UK and Yamaguchi University Graduate School of Medicine, Ube City, Yamaguchi, Japan; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Neurotrophic Keratitis, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Neurotrophic Keratitis Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Prevalent Cases of Neurotrophic Keratitis
• Total Diagnosed Prevalent Cases of Neurotrophic Keratitis
• Gender-specific Diagnosed Prevalent Cases of Neurotrophic Keratitis
• Severity-specific Diagnosed Prevalent cases of Neurotrophic Keratitis

Neurotrophic Keratitis Report Key Strengths

• 11 years Forecast
• The 7MM Coverage 
• Neurotrophic Keratitis Epidemiology Segmentation 

Neurotrophic Keratitis Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Neurotrophic Keratitis? What will be the growth opportunities across the 7MM concerning the patient population of Neurotrophic Keratitis?
• What is the historical and forecasted Neurotrophic Keratitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the diagnosed prevalent cases of Neurotrophic Keratitis in Japan lower than the US?
• Which country has a high patient share for Neurotrophic Keratitis?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Neurotrophic Keratitis prevalence cases in varying geographies over the coming years.
• A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Neurotrophic Keratitis, along with diagnosed prevalence of Neurotrophic Keratitis Based on severity of airflow limitation and diagnosed prevalence of Neurotrophic Keratitis based on symptoms and exacerbation history.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.